---
title: "Biodexa wins Health Canada approval to expand Serenta Phase 3 FAP trial into Canada"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291145787.md"
description: "Biodexa Pharmaceuticals has received Health Canada approval to expand its registrational Phase 3 Serenta trial for familial adenomatous polyposis (FAP) into Canada. The study aims to enroll 168 patients, with 73 already enrolled. This expansion will add three to four clinical sites in Canada to the existing 29 active recruiting centers in the US and Europe."
datetime: "2026-06-29T12:30:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291145787.md)
  - [en](https://longbridge.com/en/news/291145787.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291145787.md)
generator: "portal-rs"
---

# Biodexa wins Health Canada approval to expand Serenta Phase 3 FAP trial into Canada

-   Biodexa received Health Canada clearance to expand its registrational Phase 3 Serenta trial in familial adenomatous polyposis into Canada. \* The study targets 168 patients; 73 enrolled so far. \* Canada is expected to add three to four clinical sites, on top of 29 active recruiting centers in the US and Europe. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodexa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290830PRIMZONEFULLFEED1001209876) on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BDRX.US](https://longbridge.com/en/quote/BDRX.US.md)

## Related News & Research

- [Biodexa FY26 H1 net loss narrows to GBP 1.84 million; R&D costs rise 75% to GBP 2.92 million](https://longbridge.com/en/news/298766899.md)
- [Optimi Health wins Health Canada authorization for Phase 2 psilocybin trial in major depression](https://longbridge.com/en/news/298597413.md)
- [Western Copper and Gold Announces Casino Project Selected for Canada Investment Summit Prospectus | WRN Stock News](https://longbridge.com/en/news/298913160.md)
- [Canadian stocks are ignoring escalating trade war with US — for now](https://longbridge.com/en/news/298793134.md)
- [SAP study shows 97% of Canadian firms not fully ready for agentic AI rollout](https://longbridge.com/en/news/298582331.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**